1/99
Looks like no tags are added yet.
Aims of using drugs on CV system and what do they adjust
rate and rhythm, force of myocardial contraction, peripheral resistance and blood flow, blood volume
ways in which drugs influence the heart
intropy, chronotropy, dromotropy, lusitropy
intropy drugs
alter contractility
chronotropy drugs
alter heart rate
dromotropy drugs
alter electrical conduction
lusitropy drugs
relaxation
types of abnormality in heart rate or rhytm
bradycardia, atrial flutter, atrial fibrillation, tachycardia, ventricular fibrillation, sinus tachycardia
types of tachycardia
sinus, ventricular, supraventricular
Supraventricular tachycardia
tachycardia above bundle
ectopic pacemaker activity as a cause of arrhythmia
damaged area of myocardium becomes depolarised and spontaneously active. latent pacemaker region activated due to ischaemia which dominates over SA node
causes of arrythmias
ectopic pacemaker activity, afterdepolarisations, re-entry loop
afterdepolarisations as a cause of arrythmia
abnormal depolarisations following AP. prolonged duration of action potential (shown as longer QT interval) causes increased cytosolic calcium and allows afterdepolarisations to occur which triggers a premature AP to fire
re-entry loop types as a cause of arrythmia
conduction delay and accessory delay
conduction delay as a result of conduction damage in unidirectional block is a re-entry mechanism as a cause of arrythmia . how does it set up a circus of excitation
bifurcation in conduction branches turn in on themselves adn cancel out the AP. however, if there is a conduction block, the signal conducts stronger on one side than the other causing a re-entry of the signal in the other side through a longer, delayed route. this side is no longer in refractory period so signal can propagate.
re-entry loops as a re-entrant mechanism for generating arrhythmias
lead to atrial fibrillation around pulmonary veins and sometimes associated with cardiac surgery where there is damage to the veins
Wolff-Parkinson-White Syndrome and bundle of kent
additional point of conductivity between atria and ventricles. an additional accessory pathway electrically links atria and ventricles known as bundle of kent which is a bypass tract
Wolff-Parkinson-White Syndrome
Most common type of ventriuclar pre-excitation sydnrome. Abnormal fast accessory conduction pathway from atria to venricle bypasses the rate-slowing AV node causing a delta wave and widening QRS with shortened PR interval. Could lead to a reentrant circuit and suprvaventicular tachy.
classes of arrhythmic drugs
1. blocks VGNa channels
2. antagonists of B-adrenoreceptors
3. block K+ channels
4. block Ca2+ channels
5. other (adenosine, Funny channel blockers and magnesium)
blocker of VGNa channels in cardiomyocytes not AVN or SAN in a negative dromatropic fashion
lidocaine, blocks Na+ channels in open or inactive state. dissociates rapidly in time for next AP which slows AP conduction across cardiomyocytes to correct arrythmias
why do class I drugs of the heart only work on cardiomyocytes not SAN or AVN
bc SAN and AVN use calcium for action potential not sodium
IV lidocaine for MI in acute settings not prophylactically as a class I drug of rhythm and rate
following MI pt presents with ventricular tachycardia as damaged areas of myocardium may be depolarised and automatically fire. as more Na+ channels are open in depolarised tissue, lidocaine blocks these channels to prevent automatic firing.
example of class II rate and rhythm controller of heart (beta adrenoreceptor antagonists)
propanolol, atenolol
b-adrenoreceptor antagonist as a class II rate and rhythm controller of heart
MI causes increased sympathetic activity. B blockers prevent ventricular arrhythmias as a result of the sympathetic activity.
block sympathetic action by antagonising b1-adrenoreceptors of the heart. also slow conduction in AVN to prevent supraventricular tachycardias.
decrease slope of pacemaker potential in SA
why are b-blockers useful for angina
reduces O2 demand and so reduces myocardial ischaemia which is beneficial following MI
class three drugs
(K+ channel blockers)
prolong action potential by blocking K+ channels. strengthen absolute refractory period so prevents another AP occurring too soon.
why K+ channel blockers (class III) not used generally
bc they can be pro-arrhymic aside from amidarone
amidarone
Class III K+ channel blocker but also has other actions. used to treat tachycardia associated with wolff parkinson-white syndrome
class IV drugs (block ca2+ channels)
decreases slope of pacemaker AP in SAN and decreases nodal conduction and force of contraction (negative inotropy). some coronary and peripheral vasodilation.
example class IV drugs (block ca2+ channels)
verapamil
why class IV drugs on SAN and not class I
because SAN has calcium channels to initiate AP not sodium channels
dihydropyridine Ca2+ channel blockers
not effective in preventing arrhythmias but act on vascular smooth muscle
adenosine as class V anti arrhythmitic
acts on A1 receptors at AVN. enhances K+ conductance resulting in hyperpolarisation of cells of conducting tissue causing stopped heart momentarily and resets rhythm.
a1 receptor of AV node
g protein coupled receptor like adrenergic. activation of a1 enhances potassium conduction
why adenosine given IV
because it is endogenous. if given orally it will just be metabolised
define heart failure
failure of heart to provide sufficient output to meet body's requirements
goal of heart failure treatment
reduce work load of heart by reducing preload and afterload using positive ionotropes to increase cardiac output with positive ionotropes or ace inhibitors
positive ionotropes used in heart failure
b-adrenergic agonists eg adrenaline and dobutamine. or cardiac glycosides for atrial fibrillation.
how do ace inhibitors reduce work load of heart
prevention of ag1 to ag2 by limiting angiotensin converting enzyme. ag2 is a vasoconstrictor and aldosterone which increases water reabsorption . so without a2 you have decrease vasomotor tone so decrease in blood pressure so reduced afterload. decreased fluid retention causes decrease in blood volume so reduced preload of the heart.
Angiotensin II Receptor Blockers (ARBs)
have similar effects to ACE inhibitors in heart failure
losartan
angiotensin 2 receptor blocker
drugs that reduce the work load of heart
b-blockers, diuretics, ace inhibitors, arbs
positive ionotropy
increase myocardial contractility
cardiac glycosides as positive ionotropes
cardiac glycosides improve symptoms but now used in atrial fibrillation
positive ionotropic drugs
cardiac glycosides, digotoxin as a prototype
digoxin as a positive ionotrope
blocks Na+/K+ase
lusitropy
relaxation of myocardium following excitation contraction coupling by removing calcium into sarcopasmic reticulum to promote relaxation. it is diastolic in function
ionotropy
contractility. systolic function
factors hat produce positive lusitropy
b-antagonists: phosphorylate phospholamban via cAMP.
phospholamban
antagonist of SERCA in non-phosphorylated state
factors that produce negative lusitropy
high cytosolic calcium, impaired sarcoplasmic reticulum calcium ATPase (serca). increased affinity of troponin C: alkalosis increases calcium sensitivity. cardiac glycosides indirectly effects via sodium pump, b-blockers
Cardiac Glycosides MOA
calcium pumped out of cells by sodium-calcium exchanger. driven by Na+ moving down conc gradient. block Na+/K+ase = rise in Na+ intracellularly so Ca+ retained in cells due to decrease in exchanger. more Ca2+ stored in SR so increased force of contraction so positive inotropic effect
how do cardiac glycosides impact on heart chronotropically
increased vasal activity through central pathway to stimulate Ach which stimulates muscarinic receptors to slow AV conduction and slow hr
drugs which increase myocardial contractility and speed of relaxation
b-adrenoreceptor agonists eg dobutamine. acts on b1 receptors
when would you use dobutamine
in cardiogenic shock, acute but reversible heart failure
how do b-adrenoreceptor agonists work
G prt coupled receptor in membrane
Gpcr
Signals through GSG protein which modulates activity of adenyl cyclase . Stimulates cAMP, promotes PKA action, phosophorylate proteins
Inc phospholamban and effects SERCA pump by inhibiting so prevents Ca2+ storage and increase in intracellular calcium increases contractility
pharmacological treating of angina by reducing work load of the heart
ACE/arb; b-blockers; ca2+ channel antagonists; organic nitrates; funny channel blockers
pharmacological treating of angina by improving blood supply to heart
ca2+ antagobists
pharmacological treating of angina by cholestrol reduction
statins
surgical interventions for angina
angiography, stents, revascularise
organic nitrates MOA
organic nitrates react with SH- (thiols) in vascular smooth muscle to release NO2- . NO2- is reduced to NO whch is a vasodilator
organic nitrate examples
glyceryl trinitrate; isosorbide mononitrate; isosorbide dinitrate
how does NO cause vasodilation
NO activates guanylate cyclase which converted to cGMP works with PKG to lower intracellular Ca2+ to relax vascular smooth muscle
NO vasodilator. how does alleviate symptoms - primary action
acts on venous system to dilate to lower preload; reduces venous pressure; which reduces workload of heart. heart fills less so force of contraction reduced according to starlings law so this reduces O2 demand
NO vasodilator. how does alleviate symptoms - secondary action
action on coronary arteries improves O2 delivery to ischaemic myocardium and acts on collateral arteries rather than arterioles
organic nitrates on collateral arteries from atheromatous plaques
plaques cause poor perfusion nitrate dilates collateral. ichaemic area blood flow increases nitrate dilates vessles to perfusion
heart conditions carry an increased risk of thrombus formation
atrial fibrillation; acute myocardial infarction; mechanical prosthetic heart valves
antithrombotic drugs for clotting cascade
IV heparin; fractured hearin (subcutaneous injection); fondaparinux; warfarin orally; dabigatran, apixaban, rivaroxaban
IV heparin
inhibits thrombin, short term action
warfarin orally MOA
blocks activation/recycling victamin K (epoxide reductase complex 1 inhibitor) inhibits synthesis or hepatic clotting factors II, VII, IX, X. used long term
Novel Oral Anticoagulants
thrombin inhibitor; factor Xa inhibitor
thrombin inhibitor: dabigatran
factor xa inhibitors: apixaban, rivaroxaban
vk clotting factors
II, VII, IX, X
antiplatelet drugs following acute MI or high risk MI
aspirin
antiplatelet drug dipyridamol how
phosphodiesterase inhibitopm
how antiplatet clopidogrel work
inhibits ADP dependent platelet aggregation
behavioural rf for heart diseases
alcohol, obesity, physical activity, tobacco use, unhealthy diet
unhealthy diet
rich in salt, sugar, fat and calories
metabolic risk factors for cvd
raised BP, raised blood sugar, raised blood lipids, overweight and obesity
rf for CVD
poverty, advancing age, sex, genetics, psychological factors (stress and depression)
primary prevention of CHD
prevents disease from occuring in those at risk eg provide smoking cessation advice to someone with no history of CHD
secondary prevention of CHD
identify high risk individuals and prevent disease progression eg provision of lipid lowering medications to those with CHD
tertiary prevention of CHD
prevent recurrence of MI. eg revascularisation after MI for severe CHD cases
policies of heart disease prevention
banning tobacco smoke from public places to protect people. warning about dangers of tobacco use. enforcing bans on tobacco advertising, raising taxes on alcohol, replacing transfat in food with polyunsaturated fat, public awareness of diet and physical activity
QRISK
primary, secondary or tertiary prevention
primary
QRISK
ethnicity, family hx, deprivation, BP treatment, BMI, RA, CKD, AF. works out 10 year risk of MI/stroke
QRISK >10%
advised to start statins
obesity/ reducing rf for HD advice
mediterranean diet, childhood obesity through change4life, low salt diets, alcohol less than 14 units a week, peer supported weight loss programmes
psychological factors in heart disease
individual differences: optimism, hostility, stress
mood: depression, anxiety
resources for psychological processes in heart disease
coping, support, religion, midfulness, hypnosis, cbt, excercise, psychotherapy, social support, motivational interviewing, neuroendocrine and immune review
biological factors in heart disease
genetics, sex, age, fhx, ethnicity, exposure to viruses and toxins, injury, medical treatment
health behaviours factors in HD
sleep, excersise, sun exposure, screening attendance, alcohol, drug use, smoking, sexual behaviours, adherence, vaccination
neuroendocrine factors in heart disease
HPA activation, cortisol, oestrogen, testosterone
immune mechanisms as factors for heart disease
immune responses, wound healing factors from cytokines
depression increases cardio events. direct pathway, hospital readmission and mortality
pro-inflammatory (chronic stressor) and associated with increased inflammatory measures (CRP, cortison), increases heart rate, glucose adn BP. parasympathetic control of heart reduced in depressed patients so increased susceptibility to cardiac arrhythmias and sudden death
how does depression increase cardiac events indirectly
increases risk of smoking, obesity, decreased exercise and adherence after cardiac event, increasing risk of atherosclerosis
dose response relationship in depression and cardiac events
more severe depression, increased risk of cardiac death
questions for depression
energy level, sleeping, mood, anxious or worried, undue pressure at home/work, difficulty unwinding after work or at the end of the day, who do you go to for support
Ornish Program for Reversing Heart Disease
non surgical or pharmalogical. dose response manner and saves money per pt
social: group support involving partners
psychological: stress management (meditation, yoga)
physical: low fat, vegetarian diet, exercise, stopping smoking
non surgical or pharmalogical HD treatment
multidisciplinarhy cardiac rehabillitation. nutrition counselling, education, RF management (eg smoking cessation) physical activity conselling, psychological interventions (stress management)
pros of multidisciplinary cardiac rehab
less time in hospital, improved QOL, reduced mortality, non surgical/pharmalogical
cons of multidiscpilinary cardiac rehab
poor attendance (travel, mental health, dislike of groups)